Cellectar Biosciences (CLRB) Stock Price, News & Analysis

Company Overview

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapeutics and oncology treatments. Its technology platform uses phospholipid ether compounds, which are designed to preferentially accumulate in cancer cells and other diseased tissues while limiting exposure to healthy tissue.

The company’s leading product candidate is iopofosine I 131, also known as CLR 131, a small-molecule radiopharmaceutical being studied for the treatment of hematologic malignancies, including relapsed or refractory multiple myeloma and certain types of lymphoma. Cellectar is also advancing additional phospholipid ether-based compounds and programs intended to support targeted imaging, drug delivery and treatment of cancer.

Founded in 2003 and headquartered in Madison, Wisconsin, Cellectar conducts its research and clinical development activities primarily in the United States, while its investigational programs may involve international clinical and regulatory activities. James Caruso serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $1.23 to $1.31
• 50-Day Range: $1.12 to $2.54
• 52-Week Range: $1.12 to $4.70
• Volume: 139,112 shs
• Average Volume: 178,653 shs
• Market Capitalization: $12.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Moderate Buy

Cellectar Biosciences Stock Analysis - MarketRank™

Cellectar Biosciences scored higher than 56% of companies evaluated by MarketBeat, and ranked 390th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cellectar Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cellectar Biosciences has a consensus price target of $11.00, representing about 739.7% upside from its current price of $1.31.

Amount of Analyst Coverage

Cellectar Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cellectar Biosciences are expected to grow in the coming year, from ($2.39) to ($2.08) per share.

Price to Book Value per Share Ratio

Cellectar Biosciences has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.86% of the float of Cellectar Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cellectar Biosciences has a short interest ratio ("days to cover") of 1.36, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cellectar Biosciences has recently increased by 58.49%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cellectar Biosciences does not currently pay a dividend.

Dividend Growth

Cellectar Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.40

News Sentiment

Cellectar Biosciences has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cellectar Biosciences this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Cellectar Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.58% of the stock of Cellectar Biosciences is held by insiders.

Percentage Held by Institutions

16.41% of the stock of Cellectar Biosciences is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/03/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CLRB
• CIK: 1279704
• Web: www.cellectar.com
• Phone: (608) 441-8120
• Fax: 608-441-8121
• Employees: 11
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cellectar Biosciences: $11.00
• High Price Target: $11.00
• Low Price Target: $11.00
• Potential Upside/Downside: +739.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -185.35%
• Return on Assets: -115.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.66
• Quick Ratio: 6.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.89 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 9,450,000
• Free Float: 9,208,000
• Market Cap: $12.38 million
• Optionable: No Data
• Beta: 0.65